Ignite Creation Date:
2025-12-24 @ 9:33 PM
Ignite Modification Date:
2026-02-20 @ 4:29 PM
Study NCT ID:
NCT02346032
Status:
COMPLETED
Last Update Posted:
2017-04-26
First Post:
2014-11-18
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Phase II Study of Refametinib, a MEK Inhibitor, as Second-line Treatment in Advanced Biliary Tract Adenocarcinoma
Sponsor:
Samsung Medical Center
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2015-06-30
Start Date Type:
ACTUAL
Primary Completion Date:
2016-09-30
Primary Completion Date Type:
ACTUAL
Completion Date:
2016-10-13
Completion Date Type:
ACTUAL
First Submit Date:
2014-11-18
First Submit QC Date:
None
Study First Post Date:
2015-01-26
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2017-04-24
Last Update Post Date:
2017-04-26
Last Update Post Date Type:
ACTUAL